Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801359 | 0.92 | L3MBTL1 (0.55) | L3MBTL1POLBNPC1ALDH1A1PSMD10 | |
| Trifluoroacetic Acid SCHEMBL23326865 | 0.89 | L3MBTL1 (0.43) | L3MBTL1POLBNPC1ALDH1A1PSMD10 | |
| Trifluoroacetic Acid SCHEMBL30801352 | 0.85 | MIF (0.45) | L3MBTL1POLBNPC1ALDH1A1APP | |
| Trifluoroacetic Acid SCHEMBL30801355 | 0.77 | MIF (0.43) | L3MBTL1POLBNPC1ALDH1A1APP | |
| SCHEMBL23326579 | 0.70 | GLA (0.46) | L3MBTL1POLBNPC1ALDH1A1APP | |
| SCHEMBL19126510 | 0.70 | PSMD10 (0.55) | L3MBTL1POLBNPC1PSMD10APP | |
| SCHEMBL21990759 | 0.67 | PKM (0.75) | NPC1ALDH1A1PKM | |
| SCHEMBL12571591 | 0.66 | CA12 (0.66) | L3MBTL1POLBNPC1NOTUM | |
| SCHEMBL23326705 | 0.66 | MAOA (0.43) | L3MBTL1POLBNPC1ALDH1A1APP | |
| SCHEMBL13606623 | 0.66 | GAA (0.57) | L3MBTL1POLBNPC1ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11885818-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-112492881-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, PTMS, MMAB | L3MBTL1 2526/4885POLB 3320/4885NPC1 3023/4885 |
| US-11885818-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | L3MBTL1 2526/4885POLB 3320/4885NPC1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.